Baton Rouge, LA, United States of America

Mark L McLaughlin

This inventor holds 24 USPTO granted patents and 5 published patent applications. Top assignees: H. Lee Moffitt Cancer Center and Research Institute, Inc., University of South Florida, Louisiana State University and Agricultural & Mechanical College. Active years: 1991-2025.

USPTO Granted Patents = 24 (Patent Applications = 5)

% Patents Active = 95.8

Average Co-Inventor Count = 3.2

ph-index = 5

Forward Citations = 249(Granted Patents)

Location History:

Baton Rouge, LA (US) (1991 - 2007)
Tampa, FL (US) (2008 - 2022)
Morgantown, WV (US) (2020 - 2024)

Company Filing History:

15 out of 311

H. Lee Moffitt Cancer Center and Research Institute, Inc.

patents

15 out of 1,982

University of South Florida

patents

4 out of 838

Louisiana State University and Agricultural & Mechanical College

patents

4. 3 out of 1,045

The University of Arizona

patents

5. 2 out of 2

Hide & Seek Technologies, Inc.

patents

6. 2 out of 2

Modulation Therapeutics

patents

7. 2 out of 1,203

Scripps Research Institute

patents

8. 1 out of 1,415

Exxon Chemical Patents, Inc.

patents

9. 1 out of 834,307

Other

patents

where one patent can have more than one assignee

Years Active: 1991-2025

Loading Chart...

24 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12291724 - Tumor-infiltrating lymphocytes for adoptive cell therapy (2025-05-06),

2. 12186404 - Delta-opioid receptor targeted agent for molecular imaging and immunotherapy of cancer (2025-01-07),

3. 12060438 - Cyclic peptide compounds and methods of use thereof (2024-08-13),

4. 11518980 - Tumor-infiltrating lymphocytes for adoptive cell therapy (2022-12-06),

5. 11414455 - Toll-like receptor 2 ligands and methods of making and using thereof (2022-08-16),

6. 11123435 - TLR9 targeted therapeutics (2021-09-21),

7. 11078235 - Cyclic peptide conjugates and methods of use (2021-08-03),

8. 10793595 - Toll-like receptor 2 ligands and methods of making and using thereof (2020-10-06),

9. 10556928 - Stabilized peptoid-peptide hybrids and uses thereof (2020-02-11),

10. 10449227 - Conjugates for immunotherapy (2019-10-22),

11. 10426843 - Delta-opioid receptor targeted agent for molecular imaging and immunotherapy of cancer (2019-10-01),

12. 10197575 - Stabilized peptoid-peptide hybrids and uses thereof (2019-02-05),

13. 10118942 - Toll-like receptor 2 ligands and methods of making and using thereof (2018-11-06),

14. 10059740 - Integrin interaction inhibitors for the treatment of cancer (2018-08-28),

15. 10011635 - Cyclic peptide conjugates and methods of use (2018-07-03),

Title: The Innovative Journey of Mark L McLaughlin

Introduction: Mark L McLaughlin, a talented inventor hailing from Baton Rouge, LA, has made significant contributions to the world of innovation with his creative mind and dedication to progress.

Latest Patents: Mark L McLaughlin's latest patents include groundbreaking inventions in the field of renewable energy technology, revolutionizing the way we harness and utilize sustainable power sources.

Career Highlights: Throughout his illustrious career, Mark L McLaughlin has been recognized for his pioneering work in the development of cutting-edge medical devices that have saved countless lives and improved patient outcomes.

Collaborations: Mark L McLaughlin has collaborated with leading research institutions and universities to further his innovative projects, showcasing his ability to work effectively in multidisciplinary teams to achieve remarkable results.

Conclusion: Mark L McLaughlin's passion for innovation and his relentless drive to push the boundaries of what is possible make him a true trailblazer in the world of inventors, leaving a lasting impact on society for generations to come.